Advertisement

Topics

Clovis Oncology's Rubraca data sets stage for label expansion

06:54 EDT 19 Jun 2017 | Reuters

(Reuters) - Positive data on Clovis Oncology Inc's ovarian cancer drug, Rubraca, from a late-stage study could help the U.S. biotech widen the use of the therapy and differentiate it against rivals, the company said on Monday.

Original Article: Clovis Oncology's Rubraca data sets stage for label expansion

NEXT ARTICLE

More From BioPortfolio on "Clovis Oncology's Rubraca data sets stage for label expansion"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Ovarian Cancer
Ovarian Cancer is cancer that starts in the female reproductive organs, the ovaries. It is the fifth most common cancer among women.  Women at risk of Ovarian Cancer are those who have had few children (or had children at an older age), carriers o...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...